Literature DB >> 23218022

Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome.

Patrick D McGorry1, Barnaby Nelson, Lisa J Phillips, Hok Pan Yuen, Shona M Francey, Annette Thampi, Gregor E Berger, G Paul Amminger, Magenta B Simmons, Daniel Kelly, Grad Dip, Andrew D Thompson, Alison R Yung.   

Abstract

OBJECTIVE: The ultra-high risk clinical phenotype is associated with substantial distress and functional impairment and confers a greatly enhanced risk for transition to full-threshold psychosis. A range of interventions aimed at relieving current symptoms and functional impairment and reducing the risk of transition to psychosis has shown promising results, but the optimal type and sequence of intervention remain to be established. The aim of this study was to determine which intervention was most effective at preventing transition to psychosis: cognitive therapy plus low-dose risperidone, cognitive therapy plus placebo, or supportive therapy plus placebo.
METHOD: A double-blind, randomized, placebo-controlled 12-month trial of low-dose risperidone, cognitive therapy, or supportive therapy was conducted in a cohort of 115 clients of the Personal Assessment and Crisis Evaluation Clinic, a specialized service for young people at ultra-high risk of psychosis located in Melbourne, Australia. Recruitment commenced in August 2000 and ended in May 2006. The primary outcome measure was transition to full-threshold psychosis, defined a priori as frank psychotic symptoms occurring at least daily for 1 week or more and assessed using the Comprehensive Assessment of At-Risk Mental States. Secondary outcome measures were psychiatric symptoms, psychosocial functioning, and quality of life.
RESULTS: The estimated 12-month transition rates were as follows: cognitive therapy + risperidone, 10.7%; cognitive therapy + placebo, 9.6%; and supportive therapy + placebo, 21.8%. While there were no statistically significant differences between the 3 groups in transition rates (log-rank test P = .60), all 3 groups improved substantially during the trial, particularly in terms of negative symptoms and overall functioning.
CONCLUSIONS: The lower than expected, essentially equivalent transition rates in all 3 groups fail to provide support for the first-line use of antipsychotic medications in patients at ultra-high risk of psychosis, and an initial approach with supportive therapy is likely to be effective and carries fewer risks. © Copyright 2013 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23218022     DOI: 10.4088/JCP.12m07785

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  47 in total

1.  [Should antipsychotics be used in prodromal stages of schizophrenia to prevent psychosis? Pro].

Authors:  M Lambert; C Correll
Journal:  Nervenarzt       Date:  2015-11       Impact factor: 1.214

2.  Staged Treatment in Early Psychosis: A sequential multiple assignment randomised trial of interventions for ultra high risk of psychosis patients.

Authors:  Barnaby Nelson; G Paul Amminger; Hok Pan Yuen; Nicky Wallis; Melissa J Kerr; Lisa Dixon; Cameron Carter; Rachel Loewy; Tara A Niendam; Martha Shumway; Sarah Morris; Julie Blasioli; Patrick D McGorry
Journal:  Early Interv Psychiatry       Date:  2017-07-18       Impact factor: 2.732

3.  Lack of evidence to favor specific preventive interventions in psychosis: a network meta-analysis.

Authors:  Cathy Davies; Andrea Cipriani; John P A Ioannidis; Joaquim Radua; Daniel Stahl; Umberto Provenzani; Philip McGuire; Paolo Fusar-Poli
Journal:  World Psychiatry       Date:  2018-06       Impact factor: 49.548

Review 4.  Attrition rates in trials for adolescents and young adults at clinical high-risk for psychosis: A systematic review and meta-analysis.

Authors:  Megan S Farris; Daniel J Devoe; Jean Addington
Journal:  Early Interv Psychiatry       Date:  2019-08-18       Impact factor: 2.732

Review 5.  Evidence-based psychotherapy for the prevention and treatment of first-episode psychosis.

Authors:  Hendrik Müller; Sonja Laier; Andreas Bechdolf
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2014-09-27       Impact factor: 5.270

6.  Preventing the onset of psychosis: not quite there yet.

Authors:  Robert K Heinssen; Thomas R Insel
Journal:  Schizophr Bull       Date:  2014-11-11       Impact factor: 9.306

7.  Biofeedback to treat anxiety in young people at clinical high risk for developing psychosis.

Authors:  Laina McAusland; Jean Addington
Journal:  Early Interv Psychiatry       Date:  2016-08-29       Impact factor: 2.732

8.  Youth-caregiver agreement on clinical high-risk symptoms of psychosis.

Authors:  Shana Golembo-Smith; Peter Bachman; Damla Senturk; Tyrone D Cannon; Carrie E Bearden
Journal:  J Abnorm Child Psychol       Date:  2014-05

Review 9.  Progress and Future Directions in Research on the Psychosis Prodrome: A Review for Clinicians.

Authors:  Kristen A Woodberry; Daniel I Shapiro; Caitlin Bryant; Larry J Seidman
Journal:  Harv Rev Psychiatry       Date:  2016 Mar-Apr       Impact factor: 3.732

10.  Early psychosis research at Orygen, The National Centre of Excellence in Youth Mental Health.

Authors:  S M Cotton; K M Filia; A Ratheesh; K Pennell; S Goldstone; P D McGorry
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2016-01       Impact factor: 4.328

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.